Home » Investors »
Corporate Profile
 |
OVERVIEWViropro Inc. (“Viropro”) operates through Viropro International Inc., a Canadian company with its Head Office in Montreal. Viropro International Inc. is specialized in the technology transfer for industrial production of affordable biological therapeutic products whose licenses have expired. The principal objective is to support pharmaceutical companies in South America, Asia, Africa and Eastern Europe, by offering them the opportunity to locally produce and commercialize therapeutic products of industrial quality at an affordable price. Viropro enables emerging markets with unmet medical needs to gain access to therapeutic biological products for the treatment of various diseases such as cancer, diabetes, chronic hepatitis, multiple sclerosis, and rheumatoid arthritis. The innovative business strategy of Viropro International Inc. is based on the acquisition of exclusive products and technological rights/licenses/patents, simultaneously with the development of key partnerships with pre-eminent players on a national and international scale. Viropro International Inc. has already concluded agreements with the Biotechnological Research Institute of the National Council of Canada (Montreal: Worldwide exclusive rights to the use of patented expression systems for the production of human Interferon beta and monoclonal antibodies; scale-up and production processes), and Intas Biopharmaceuticals of India (codevelopment, outlicensing and sale of Mab CD20). CORPORATE SUMMARY
STOCK INFORMATIONhttp://www.otcbb.com/asp/quote_module.asp?symbol=vpro NOTE & DISCLOSURESThis document contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investor should consult the Company’s quarterly and annual filings with the U.S. security commission for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. |